| Philip George |
Philip George is currently the Chief Strategy Officer at BioCryst Pharmaceuticals, Inc. He completed his undergraduate degree at the University of Bristol and his MBA at the London Business School. |
| Salisa Hauptmann |
Salisa Hauptmann is currently working as the Chief Compliance Officer & Vice President at Merz Pharmaceuticals LLC and Merz, Inc. She is also currently serving as the Chief Regulatory Officer at BioCryst Pharmaceuticals, Inc. Ms. Hauptmann has a graduate degree from Webster University and an undergraduate degree from the University of California, Davis. |
| Ryan Arnold |
Ryan Arnold is currently the Chief Medical Officer at BioCryst Pharmaceuticals, Inc. He previously worked as a Principal at Biogen, Inc. and as a Vice President-Medical Affairs at SAGE Therapeutics, Inc. Dr. Arnold holds a doctorate degree from Michigan State University and an undergraduate degree from Oakland University (Michigan). |
| Stephanie Angelini |
Stephanie Angelini is currently the Chief People Officer at BioCryst Pharmaceuticals, Inc. She previously worked as a Partner-Human Resources Business at Oath, Inc. and as a Senior Partner-Consumer & Content Human Resources at Yahoo Holdings, Inc. She obtained an undergraduate degree from North Carolina State University. |
| Charles K. Gayer |
Charles K. Gayer is currently the Chief Commercial Officer at BioCryst Pharmaceuticals, Inc. He started this position in 2020. Prior to his current role, he obtained an undergraduate degree from Princeton University and an MBA from The Fuqua School of Business. |
| Anthony J. Doyle |
Anthony J. Doyle's current job is as the Chief Financial Officer, Treasurer & PAO at BioCryst Pharmaceuticals, Inc. Formerly, he worked as the Chief Financial Officer at World Book, Inc. from 2012 to 2014, and as the Chief Financial Officer at Worldwide Clinical Trials Holdings, Inc. from 2014 to 2020. He also held a position as a Manager-Healthcare Solutions Global Program at GE Healthcare, Inc. In terms of education, Mr. Doyle attended Dublin City University and NEOMA Business School, where he completed undergraduate degrees. |
| Jinky Ang Rosselli |
Jinky Ang Rosselli is currently the Director at Triangle Residential Options for Substance Abusers, Inc. and the Director at Durham Medical Orchestra Foundation. She also holds the position of Chief Data & Insights Officer at BioCryst Pharmaceuticals, Inc. since 2021. Previously, she worked as the Senior Director-Global Business Intelligence at United Therapeutics Corp. Ms. Rosselli completed her undergraduate degree at Duke University and her graduate degree at Yale School of Medicine. |
| Robert Clayton Fletcher |
Robert Clayton Fletcher is currently the Chief Business Development Officer at BioCryst Pharmaceuticals, Inc. He previously worked as a Senior Associate Scientist at Centocor, Inc. from 1991 to 1993, a Senior Project Manager at Smithkline Beecham Plc from 1997 to 2001, and as the VP-Business Development & Project Management at Shire ViroPharma, Inc. from 2001 to 2014. From 2015 to 2020, he was the SVP-Business Development & Strategic Planning at Idera Pharmaceuticals, Inc. He also held the position of SVP-Business Development & Project Management at Viropharma, Inc. He received his undergraduate and graduate degrees from Wake Forest University in 1985 and 1990, respectively. |
| Nancy J. Hutson |
Nancy J. Hutson is currently the Chairman at BioCryst Pharmaceuticals, Inc. and the Vice Chairman-Trustees Board at Illinois Wesleyan University. She is also an Independent Director at PhaseBio Pharmaceuticals, Inc., Endo International Plc, Clearside Biomedical, Inc., and Lipidio Pharmaceuticals, Inc. Additionally, she serves as a Director at Thirona Bio, Inc., a Scientific Advisor at Hatteras Venture Partners, and is the Owner of Ledyard Co. In her former positions, Dr. Hutson served as an Independent Director at Cubist Pharmaceuticals LLC from 2011 to 2015, and at Endo Health Solutions, Inc. from 2011 to 2014. She was also a Director at Inspire Pharmaceuticals, Inc. from 2006 to 2011. Furthermore, she held positions as a Director at Endo Pharmaceuticals, Inc., the University of Connecticut Health Center, Connecticut Business & Industry Association, African Medical & Research Foundation, and Planned Parenthood of Connecticut, Inc. Prior to these roles, she worked at Pfizer Inc. from 1981 to 2006, where she held the position of Senior VP-Global Research & Development. Dr. Hutson obtained a doctorate degree from Vanderbilt University and an undergraduate degree from Illinois Wesleyan University. |
| Yarlagadda S. Babu |
Yarlagadda S. Babu is currently the Chief Discovery Officer at BioCryst Pharmaceuticals, Inc. He previously worked as a Professor at The University of Alabama at Birmingham. He holds a doctorate degree from the Indian Institute of Science. |
| William P. Sheridan |
William P. Sheridan's current job is as the Chief Development Officer at BioCryst Pharmaceuticals, Inc. His former job was as the Vice President-North American Medical Affairs at Amgen, Inc. He also served as the Head-Bone Marrow Transplant Service at Royal Melbourne Hospital. Dr. Sheridan holds a doctorate degree from the University of Melbourne. |
| Helen M. Thackray |
Helen M. Thackray is currently the Chief Research & Development Officer at BioCryst Pharmaceuticals, Inc. She is also a Member-Institutional Review Board at Holy Cross Hospital (Maryland). In addition, she is an Assistant Clinical Professor at GW School of Medicine & Health Sciences. Previously, Dr. Thackray served as an Independent Director at ImmunoGen, Inc. from 2021 to 2024. She was also the Vice President-Clinical Product Development at Biosynexus, Inc. from 2001 to 2006. From 2006 to 2021, she held the position of Chief Medical Officer & SVP-Clinical Development at GlycoMimetics, Inc. She was also a Member-Institutional Review Board at the National Center for Health Statistics. Dr. Thackray obtained her undergraduate degree from Stanford University and her doctorate from GW School of Medicine & Health Sciences. |
| Jon P. Stonehouse |
Jon P. Stonehouse's current job(s) include being the President, Chief Executive Officer & Director at BioCryst Pharmaceuticals, Inc. and the Director at The North Carolina Museum of Life & Science, Inc. Mr. Stonehouse's former job(s) include being the Chairman at Bellicum Pharmaceuticals, Inc. from 2022 to 2024. He also worked as a Director at AstraZeneca PLC, Precision BioSciences, Inc., Astra Merck, Inc., Merck & Co., Inc., Merck KGaA, and EMD Pharmaceuticals, Inc.Mr. Stonehouse completed his undergraduate degree at the University of Minnesota. |
| Amy E. McKee |
Amy E. McKee is an Independent Director at BioCryst Pharmaceuticals, Inc. since 2021. She is also the Chief Medical Officer & Head-Oncology Center at PAREXEL International Corp. since 2019. Previously, she served as the Deputy Director-Oncology Center of Excellence at the US Food & Drug Administration from 2018 to 2019. Dr. McKee completed her undergraduate degree at Middlebury College and holds a doctorate from Tulane University School of Medicine. |
| Vincent J. Milano |
Vincent J. Milano is currently the Chairman of Life Science Cares Philadelphia. He is also an Independent Director at BioCryst Pharmaceuticals, Inc., a Director at Biotechnology Innovation Organization, and an Independent Director at Aclaris Therapeutics, Inc. Mr. Milano previously served as the President, Chief Executive Officer & Director of Idera Pharmaceuticals, Inc. from 2014 to 2022. He was also the Chairman, President & Chief Executive Officer of Shire ViroPharma, Inc. from 2008 to 2014. Additionally, he held the position of Chairman-Elect at Life Sciences Pennsylvania from 2011 to 2012. Mr. Milano was the Chairman of Aceragen, Inc. and a Director at BravoSolution US, Inc. from 2003 to 2008. He served as an Independent Director at Vanda Pharmaceuticals, Inc. from 2010 to 2019 and as a Director at Venatorx Pharmaceuticals, Inc. from 2013 to 2022. He was also an Independent Director at Spark Therapeutics, Inc. from 2014 to 2019. Prior to his roles in the pharmaceutical industry, Mr. Milano worked as a Senior Manager at KPMG LLP from 1985 to 1996. Mr. Milano obtained his undergraduate degree from Rider University. |
| Stephen J. Aselage |
Stephen J. Aselage is an Independent Director at BioCryst Pharmaceuticals, Inc., and a Director at Patara Pharma LLC and Acuitas Therapeutics, Inc. He was the Chief Executive Officer & Director at Retrophin LLC, Chief Executive Officer at Kyalin Biosciences, Inc., and Chairman at Acer Therapeutics, Inc. He was also a Director at APT Pharmaceuticals, Inc., Opexa Therapeutics, Inc., Travere Therapeutics, Inc., and National Pku Alliance. He worked as a Sales Manager at Genentech, Inc. and Rorer Pharmaceuticals, Inc. and was the Senior VP-North American Sales & Marketing at SangStat Medical Corp. and Genzyme Corp. He was the Executive VP-Global Commercial Operations at CTI BioPharma Corp. and the Chief Business Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. He earned his undergraduate degree from the University of Notre Dame in 1973. |
| George B. Abercrombie |
George B. Abercrombie is currently an Independent Director at BioCryst Pharmaceuticals, Inc. and a Director at Physicians Interactive Holdings LLC. He is also a Director at the North Carolina Glaxosmithkline Foundation, Hessian Pharmaceuticals, Inc., and the North Carolina Board of Science & Technology. Additionally, he serves as an Adjunct Professor at The Fuqua School of Business. In his former positions, Abercrombie served as the President & CEO-Pharmaceuticals Operations at Roche Holding AG. He was also the President & Chief Executive Officer at Hoffmann-La Roche, Inc. from 2001 to 2009. Abercrombie held the position of President & Chief Executive Officer at Roche Laboratories, Inc. and Vice Chairman at Project HOPE-The-People-To-People Health Foundation, Inc. He has also served as a Director at Vical, Inc., Inspire Pharmaceuticals, Inc., DemeRx, Inc., Brickell Subsidiary, Inc., OCERA Therapeutics LLC, Alaunos Therapeutics, Inc., Pharmaceutical Research & Manufacturers of America, Aptus Health, Inc., Tranzyme Pharma, Inc. (Canada), Johns Hopkins Bloomberg School of Public Health, Fresh Tracks Therapeutics, Inc., and Merck & Co., Inc. Abercrombie was the Chief Commercial Officer & Senior Vice President at Innoviva, Inc. from 2014 to 2018 and the Senior Vice President-US Commercial Operations at Glaxo Wellcome, Inc. from 1993 to 2001. Abercrombie holds an MBA from Harvard University and an undergraduate degree from The University of North Carolina at Chapel Hill. |
| Theresa Marie Heggie |
Theresa Marie Heggie is currently an Independent Director at BioCryst Pharmaceuticals, Inc. She is also a Co-Managing Director at Alnylam Germany GmbH and a Director at Alnylam UK Ltd. Additionally, she serves as a Member-Supervisory Board at ProQR Therapeutics NV. In her former positions, Ms. Heggie was the Chief Executive Officer at Shire Orphan Therapies GmbH from 2008 to 2009. She also held the position of Chief Executive Officer at Freeline Therapeutics Ltd. Furthermore, she served as the Chief Executive Officer & Director at Freeline Therapeutics Holdings Plc from 2020 to 2021. Ms. Heggie was an Independent Non-Executive Director at Swedish Orphan Biovitrum AB from 2016 to 2017. She also worked as the Vice President-Global Marketing at Baxter International, Inc. and as a Principal at Janssen Pharmaceuticals, Inc. Ms. Heggie held the position of Senior Vice President-Global Commercial Operations at Shire Plc from 2005 to 2008. She was the Chief Marketing & Strategy Officer at The British United Provident Association Ltd. from 2013 to 2016. Additionally, she served as the Senior Vice President, Head-EMEA & Canada Region at Alnylam Pharmaceuticals, Inc. from 2017 to 2020. Ms. Heggie was the Senior Vice President-Global Commercial Operations at Shire Human Genetic Therapies, Inc. from 2010 to 2013. She also worked as a Principal at Ohmeda Pharmaceuticals. Ms. Heggie completed her undergraduate degree at Cornell University. |
| A. Machelle Sanders |
A. Machelle Sanders is an Independent Director at BioCryst Pharmaceuticals, Inc. and the Secretary at The North Carolina Department of Commerce. She previously served as an Independent Director at Radius Health, Inc., NVN Liquidation, Inc., and the North Carolina Department of Administration. She was also the Director at The North Carolina Biotechnology Center and the Vice President-Manufacturing & General Manager at Biogen, Inc. Ms. Sanders holds an undergraduate degree from North Carolina State University and a graduate degree from Pfeiffer University. |
| Steven K. Galson |
Steven K. Galson is currently serving as an Independent Director at BioCryst Pharmaceuticals, Inc. since 2021 and at Elephas Biosciences Corp. since 2022. Previously, he held positions as an Independent Director at Vanda Pharmaceuticals, Inc. from 2011 to 2015, Director at The National Board of Medical Examiners, Inc., Deputy Director at the Center for Drug Evaluation & Research, Director-Science Coordination & Policy Office at the United States Environmental Protection Agency, and Independent Director at InSilico Medicine Hong Kong Ltd. He also served as the Director of the US Food & Drug Administration from 2001 to 2007 and as the Senior VP-Global Regulatory Affairs & Safety at Amgen, Inc. from 2014 to 2021. Additionally, he held positions such as Senior Vice President-Civilian Health Operations at Leidos, Inc. in 2010, Chief Health Scientist at Science Applications International Corp., Chief Medical Officer at the Environmental Protection Agency and the US Department of Energy, and Chief Operating Officer at ProQR Therapeutics NV from 2021 to 2022. Dr. Galson obtained his undergraduate degree from Stony Brook University, a doctorate from the Icahn School of Medicine at Mount Sinai in 1983, and a graduate degree from Harvard T.H. Chan School of Public Health in 1990. |
| Alan G. Levin |
Alan G. Levin currently works at BioCryst Pharmaceuticals, Inc., as Independent Director from 2020, Diffusion Pharmaceuticals LLC, as Director from 2015, Critical Path Institute, as Director, American Management Association, as Member, and Pfizer (St. Louis), as Senior VP-Finance & Strategic Management from 2011. Mr. Levin also formerly worked at Actylis Corp., as Non-Executive Chairman from 2018 to 2019, Penwest Pharmaceuticals Co., as Director, HealthTronics, Inc., as Director, God's Love We Deliver, as Director, RestorGenex Corp., as Director, Diffusion Pharmaceuticals, Inc., as Independent Director, Pfizer Inc., as CFO, Treasurer, SVP-Finance & Strategic Management from 1987 to 2007, Endo Health Solutions, Inc., as Chief Financial Officer & Executive Vice President from 2009 to 2013, moksha8 Pharmaceuticals, Inc., as Chief Financial Officer & Executive Vice President, and Endo Pharmaceuticals, Inc., as Chief Financial Officer. Mr. Levin received his undergraduate degree from Princeton University and graduate degree from The Leonard N Stern School of Business. |
